Sutro Biopharma's SWOT analysis: promising pipeline drives stock ...

Dec 15, 2024 · Sutro Biopharma's SWOT analysis: promising pipeline drives stock outlook. ... Sutro Biopharma's SWOT analysis: promising pipeline drives stock outlook. SWOT Analysis. …

$2.02
OFF

Sutro Biopharma Company Profile: Overview And Full News Analysis

2 weeks from now

Dec 18, 2024 Sutro Biopharma stock hits 52-week low at $2.02. Publisher ... Dec 16, 2024 Sutro Biopharma's SWOT analysis: promising pipeline drives stock outlook. Publisher Investing.com. …

ourcrowd.com

$17
OFF

Strong Buy Rating For Sutro Biopharma Amid Promising Trial …

2 weeks from now

Dec 11, 2024 · Analyst Reni Benjamin of JMP Securities reiterated a Buy rating on Sutro Biopharma (STRO – Research Report), retaining the price target of $17.0...

businessinsider.com

$5
OFF

Sutro Biopharma Inc (STRO) Stock Message Board - InvestorsHub

2 weeks from now

Jan 1, 2025 · "According to current market analysis, Sutro Biopharma Inc. (STRO), a clinical-stage biopharmaceutical company currently trading under $5, is considered a potential …

advfn.com

FAQs about Sutro Biopharma's SWOT analysis: promising pipeline drives stock ... Coupon?

Who owns Sutro Biopharma stock?

In the past three months, Sutro Biopharma insiders have not sold or bought any company stock. Only 5.90% of the stock of Sutro Biopharma is held by insiders. 96.99% of the stock of Sutro Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. ...

How did Sutro Biopharma's stock perform in 2025?

Sutro Biopharma's stock was trading at $1.84 at the beginning of 2025. Since then, STRO stock has increased by 10.9% and is now trading at $2.04. How were Sutro Biopharma's earnings last quarter? Sutro Biopharma, Inc. (NASDAQ:STRO) posted its quarterly earnings data on Tuesday, August, 13th. ...

Is Sutro Biopharma a good buy?

Sutro Biopharma scored higher than 93% of companies evaluated by MarketBeat, and ranked 78th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Sutro Biopharma has received a consensus rating of Moderate Buy. ...

Should you buy Sutro Biopharma (Stro) stock?

Analyst Reni Benjamin of JMP Securities reiterated a Buy rating on Sutro Biopharma (STRO – Research Report), retaining the price target of $17.00. Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks! ...

What is Sutro Biopharma's news sentiment?

Sutro Biopharma has a news sentiment score of 0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.84 average news sentiment score of Medical companies. ...

Who is Sutro Biopharma?

Begin your TipRanks Premium journey today. Sutro Biopharma (STRO) Company Description: Sutro Biopharma Inc. engages in the drug discovery, development and manufacturing of pharmaceutical products. Its products technologies include XpressCF, anti-body drug conjugates, bispecifics & engineered antibodies and cGMP facility. ...